Sanuwave Health (Nasdaq: SNWV) sells UltraMIST, a non-contact ultrasound wound-care system that Medicare pays for under one billing code, CPT 97610. On October 7, 2026, Deep Sail Capital (@DeepSailCapital) flagged possible "sunshine ahead" for the battered stock if Medicare reverses a proposed cut to that code, and deep-value investor Michael Bigger (@biggercapital) has argued the cut rests on a weak data point. The catalyst is the final 2027 Physician Fee Schedule, which Sanuwave expects in the fourth quarter of 2026.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Sanuwave Health, Inc., SNWV, Nasdaq.
- Situation type: A small-cap stock whose next leg depends on one regulatory decision about one Medicare code.
- The call: Deep Sail Capital leans long, conditional on Medicare (CMS) reversing its proposed cut, while openly admitting past losses on the name.
- Price: SNWV closed at $5.62 on October 9, 2026, down from a $45.00 close in August 2025.
- Size: About 8.6 million shares were outstanding at June 30, 2026, which puts the market value near $48 million at that close.
- The proposal: CMS proposed cutting the 97610 office payment from about $397 to about $316 for 2027, with more cuts in 2028, largely by repricing a supply input from $320.18 to about $100.
- Listing pressure: Nasdaq told Sanuwave on September 23, 2026 that its market value of listed securities was below $50 million; it has until March 22, 2027 to regain compliance.
Is SNWV a good bet right now?
It is a wager on how a regulator resolves a comment fight, not on a quarter of earnings. If CMS keeps the supply input near its old level, phases the change, or sends the code back for review, today's price may already discount too much damage. If CMS finalizes the cut as proposed, the office and mobile wound-care channel that buys most of Sanuwave's systems could shrink further.
The balance sheet raises the stakes. At June 30, 2026, Sanuwave reported $9.4 million of cash against about $18.5 million of term loan debt and withdrew its 2026 guidance, according to its second-quarter release. A company in that spot may need new capital, which could dilute shareholders at a low price.
Why do some investors think the cut could be reversed?
- The input looks thin. The roughly $100 supply figure traces to a RAND analysis that leaned on a company investor slide rather than invoices for a full course of treatment, the bulls argue.
- Clinicians objected on the record. Michael Bigger's long-form piece counts more than 20 public comment letters opposing the cut, including from Mayo Clinic and Baylor St. Luke's clinicians, and none in favor. Bigger discloses, "We are long a sizable position in SNWV."
- A Mayo letter drew attention. Kingdom Capital (@kingdomcapadv) highlighted a supportive Mayo Clinic comment letter in the docket.
- Usage held up. Sanuwave said applicator revenue rose 13% to $7.3 million in the second quarter, on record applicator volumes, even as system sales fell to 82 units from 116.
- Mixed CMS signals. CMS proposed a 14% increase in the hospital outpatient rate for the same code, and management has said a hospital push could support revenue at "10-20x current rates," per Bigger's write-up.
Who's making this call and why?
Deep Sail Capital describes itself on X as a quality, growth and microcap investor running a long/short fund. Its October 7 post said, "Sunshine ahead maybe, if the CMS reimbursement is reversed?" In the same post the account conceded it has lost badly on the stock and added, "you should likely not listen to me." That candor is part of the story: the long case is a conditional bet on a rule, not a claim that the business is fine.
Track record. In our tracking of Deep Sail Capital's public calls, the account is 13-12 (a .520 win rate) on 25 calls scored at 180 days against the S&P 500, with an average edge of +8.9 percentage points. Twelve newer calls are 9-3 on a provisional basis. See the Market Calls scoreboard.
Who disagrees?
Compounders Journal (@compoundersjrnl) wrote, "I never understood the economics for $SNWV machine in a private clinic." In a follow-up, the account argued that a treatment ties up a room for about 30 minutes for roughly $150 of net revenue, a poor trade for a busy practice even before any cut.
Kingdom Capital, though it flagged the Mayo letter, also asked the hard question in a follow-up: "what's the IP worth if CMS goes to $100?" Other risks include used systems from closed practices competing with new sales, the debt load, and the Nasdaq listing deadline.
What are the key facts to verify?
- The final 2027 Physician Fee Schedule entry for CPT 97610, especially the supply input that the proposal would cut from $320.18 to about $100.
- Sanuwave's second-quarter 2026 results, including cash, debt and the withdrawn guidance.
- The Nasdaq notice in the company's September 2026 8-K.
- The public comment letters on the proposed rule, such as the Mayo letter Kingdom Capital cited.
- Whether system sales stabilize and whether management reinstates guidance after the final rule.
What would prove it right or wrong?
Right: CMS keeps the supply input close to $320.18 or phases the change, Sanuwave reinstates guidance, the market value climbs back above $50 million and holds, and the company avoids a deeply discounted equity raise.
Wrong: CMS finalizes the cut as proposed, system sales keep falling, the company raises equity near current prices, or it fails to regain Nasdaq compliance by March 22, 2027.
This is journalism and commentary, not investment advice. We hold no position unless stated.